2002
DOI: 10.1016/s1569-9056(02)80436-5
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and tolerability of propiverine in children suffering from overactive bladder - a double-blind, randomised, clinical trial versus oxybutynin and placebo

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
5
0
1

Year Published

2004
2004
2012
2012

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(6 citation statements)
references
References 0 publications
0
5
0
1
Order By: Relevance
“…[19] in adults with neurogenic conditions. Also in children with non‐neurogenic [12] or neurogenic [10] conditions, this distinct advantage of propiverine over oxybutynin was confirmed. All cited studies consistently reported two to four times greater incidence rates of ADRs for oxybutynin than propiverine.…”
Section: Discussionmentioning
confidence: 86%
See 2 more Smart Citations
“…[19] in adults with neurogenic conditions. Also in children with non‐neurogenic [12] or neurogenic [10] conditions, this distinct advantage of propiverine over oxybutynin was confirmed. All cited studies consistently reported two to four times greater incidence rates of ADRs for oxybutynin than propiverine.…”
Section: Discussionmentioning
confidence: 86%
“…A more favourable tolerability and safety profile has been reported for propiverine [6], a compound with a dual mode of action, with anticholinergic and calcium‐channel‐modulating effects [7]. In children, propiverine has been extensively investigated, especially in neurogenic [8–10], but also in non‐neurogenic conditions [11,12]. Recently, Marschall‐Kehrel et al.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Batinic et al [64] compared the efficacy and tolerability of propiverine with that of oxybutynin and placebo in children with OAB. 266 children (propiverine (n = 85) 10 mg b.i.d.…”
Section: Propiverinementioning
confidence: 99%
“…Für die Wirksubstanz Propiverin zeigte sich in einer kontrollierten Studie bei 50% der Patienten eine signifikante Reduktion inkontinenter Episoden pro Woche um mehr als 50% [5]. In einer neueren doppelblinden, randomisierten Untersuchung [2] ging zwar die Zahl inkontinenter Episoden unter Therapie mit Propiverin zurück (im Durchschnitt von 11,2 auf 6,4), der Effekt war jedoch gegenüber Placebo nicht signifikant.…”
Section: Tagesstationäres Blasentrainingunclassified